# Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

> **NCT00193622** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 50 (—)

## Conditions studied

- Neoplasms, Unknown Primary

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00193622
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-09
- **Final completion:** 2009-01
- **Target enrollment:** 50 (—)
- **Last updated:** 2010-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193622, "Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00193622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*